News archive

09 Mar 2010

Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease

01 Mar 2010

Actelion to host Conference Call/ Audiocast on BUILD-3 Study Results at 15.30 hrs Swiss time

01 Mar 2010

BUILD-3 study with bosentan in idiopathic pulmonary fibrosis does not meet primary endpoint

18 Feb 2010

Actelion publishes Annual Report 2009

18 Feb 2010

Actelion announces Full year 2009 financial results

05 Feb 2010

Actelion to Present at the 12th Annual BIO CEO & Investor Conference

12 Jan 2010

Zavesca® (miglustat) receives positive vote from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee for the treatment of Niemann-Pick type C disease

11 Jan 2010

Actelion to Present at the 28th Annual J.P. Morgan Healthcare Conference

22 Dec 2009

Actelion reports arbitration results between subsidiary CoTherix, Inc. and Asahi Kasei Pharma Corporation

21 Dec 2009

Investigational dual orexin receptor antagonist almorexant meets primary endpoint in two-week phase III study in patients suffering from primary insomnia

08 Dec 2009

Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Phase IIb dose-finding study in multiple sclerosis already ongoing - Roche to leave S1P1 alliance following comprehensive portfolio review and prioritization

19 Nov 2009

US Food and Drug Administration grants priority review for Actelion's miglustat in Niemann-Pick type C disease

20 Oct 2009

Actelion announces 9-month financial results 2009

09 Oct 2009

Dose-finding Phase IIb study started in patients with multiple sclerosis - Actelion/Roche S1P1 alliance achieves clinical milestone

08 Sep 2009

Actelion updates US Healthcare Professionals for patients with type 1 Gaucher disease - Information on the potential use of Zavesca® (miglustat) oral capsule to address the supply shortage of intravenous enzyme replacement therapy (imiglucerase)

10 Aug 2009

Tracleer receives label extension in the US for the treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension

10 Aug 2009

Ventavis (Iloprost) in pulmonary arterial hypertension receives US approval for increased 20 mcg/ml strength formulation

21 Jul 2009

Actelion announces Half Year financial results 2009

17 Jul 2009

Actelion's PGI2 receptor agonist demonstrates efficacy in pulmonary arterial hypertension patients - Morbidity-Mortality Phase III study to be initiated before year-end

06 Jul 2009

Tracleer (bosentan) receives EU approval for pediatric formulation - the first and only licensed pulmonary arterial hypertension therapy for children

Page : 1 2 3 4 5 6 7 8 9 10

Top of page Print pageSend this page to a friendBookmark with del.icio.usBookmark with diggBookmark with MISTER WONG

Contact

Media Relations

Actelion Pharmaceuticals Ltd

Gewerbestrasse 16

CH-4123 Allschwil

Switzerland

Phone:+41 61 565 62 62

Fax:+41 61 565 65 07

Contact us online How to get to us

Related links

Actelion press releases Press releases in German